2 x 2M buys - 1M left - all MMs bar 2 moved up to .0002

Shattering Records: CME Group's Latest Milestone Well, here's a juicy nugget for your investment playbook. On September 4, 2026, CME Group proved, once again, why they're the big dog in the derivatives yard, announcing a new record in FX open interest—4,410,167 contracts! This tops the previous mark of 4,269,622 contracts set just a few months back. The futures and...

Buying Coastal Property: A Balancing Act Ah, the dream of owning a piece of the beach in sunny South Florida. It sounds glamorous—something to brag about at the next family gathering. But let me tell you, diving into coastal property ownership isn't just about sipping cocktails by the ocean. It's about handling a fair share of headaches most folks don't anticipate....

Allegations Stir the Pot: York Space Systems Under Fire Now we're sailing into choppy waters with York Space Systems (YSS). There's a full-blown ruckus stirring as investors take aim at the company, thanks to a class action lawsuit alleging securities fraud. The legal beagles from Glancy Prongay Wolke & Rotter LLP are spearheading this effort, claiming that York pulled...

Are Dentsply Sirona Insiders on Thin Ice? The stock market's a tumultuous sea, and right now, it seems like some of those at the helm of Dentsply Sirona Inc. might be rocking the boat a bit too much. Let me tell you, navigating these corporate storms isn't for the faint-hearted. The latest noise coming from Halper Sadeh LLC suggests that some directors and officers over...

Hims Faces Harsh Lessons With FTC Lawsuit There's trouble brewing in the world of telehealth, and Hims & Hers Health (NYSE: HIMS) is right at the eye of the storm. They've gone from a darling of digital health to a pariah faster than you can say 'data breach.' On July 29, 2026, they took a hit so hard you’d think the company stepped into the ring with a heavyweight...

GBC 2026: Korea's Giant Leap in Bio Innovation Well, there wasn't a dull moment at the 'Global Bio Conference 2026' in Seoul. Picture a melting pot where 5,600 participants from 19 countries converged to chat about the latest and greatest in biopharma innovation and regulatory strategies. That's not a setup you see every day, mind you. This event packed the room with...

Unveiling the Art Spectacle in Lyon Alright, buckle up folks, because the 18th Lyon Biennale – Contemporary Art is about to take the stage in grand fashion. Starting on the 19th of September, this art fiesta is not just any exhibit; it's an eleven-venue citywide takeover that runs until the 13th of December, and it is poised to shake up the art scene like a good splash...

Legal Drama Clears Market Path Well, folks, here’s a win from the trenches for Cocrystal Tech that can shake up the nutraceutical market. Kaneka's grip on the patent for their ubiquinol concoctions just got busted by the U.S. District Court. They ruled that Kaneka's claims lacked utility and enablement, essentially saying they were pitching an untested hypothesis as an...

Science and Technology at the Forefront Saturday nights usually have folks kicking back with some reality shows or maybe cheering on their favorite sports team. But this September 12, savvy viewers have a chance to dive deep into the guts of cutting-edge science and tech on Bloomberg Television. We're talking about 'Advancements with Ted Danson'—where science isn’t...

Regeneron's Meltdown: A Bitter Pill for Investors Let’s dive headlong into the mess Regeneron Pharmaceuticals (NASDAQ:REGN) finds itself in—a classic nightmare scenario for investors. News broke like an old valve bursting, and suddenly, the market's love for Regeneron ran ice-cold. Who's to blame this time? Well, you might want to point a finger at the failed Phase 3...

Revolutionary Advances in Gene Therapy for Danon Disease Recent findings from groundbreaking research at Children's Hospital of Philadelphia reveal a promising new approach in tackling Danon disease, a complex genetic disorder predominantly affecting young males. The study not only highlights the potential of gene therapy—specifically a novel treatment known as...

Biohaven Breaks New Ground with BHV-8100 There’s a fresh buzz in the biopharma world as Biohaven Ltd. kicks off first-in-human dosing for their novel drug, BHV-8100. This is no small feat, and it could potentially shake up the landscape of treatments for systemic and central nervous system disorders. You know there’s weight behind a drug when it’s aiming for those...

Exciting Announcement from Nasdaq Nasdaq recently shared significant news regarding its upcoming 2026 Investor Day. Scheduled for the morning of February 25, 2026, this highly anticipated event will take place at the Nasdaq Global Headquarters in Times Square. This annual gathering is essential for investors as it provides insights into the company's strategic direction...

Acreage Holdings Restructures Debt Agreement with Canopy USA Acreage Holdings (OTC: ACRGF), Inc. is a diversified cannabis company, recently announced a strategic amendment to its debt agreement with Canopy USA, LLC, which impacts the payment terms of its outstanding obligations. This pivotal financial maneuver came into effect recently and is a reflection of the...

Understanding the Growth of the Chlorella Market Chlorella occupies an important place in the sphere of superfoods. This vibrant freshwater alga, famous for its rich nutritional profile, plays a vital role in the health and wellness trend that is sweeping across the globe. It is known for its presence in pills, powders, capsules, and liquid extracts, marking its...